TD Cowen Reiterates "Buy" Rating on Vaxcyte (PCVX) With $50 PT

With significant upside potential and hedge fund interest, Vaxcyte, Inc. (NASDAQ:PCVX) secured a spot on our list of the 15 stocks set to explode in 2026.

On November 5, 2025, TD Cowen analyst Tara Bancroft reiterated her “Buy” rating on Vaxcyte, Inc. (NASDAQ:PCVX) with a $50 price target.

The analyst cited positive Phase II data from the company’s VAX-24 infant vaccine trials. With the VAX-24 meeting non-inferiority criteria for most serotypes, the study demonstrated robust immune responses and a dose-dependent increase in immunogenicity, with no evidence of carrier suppression. With Phase III results expected in 2026, she believes the data reinforce Vaxcyte, Inc. (NASDAQ:PCVX)’s optimized dosing approach for its VAX-31 program. Moreover, she believes the vaccine’s competitive edge over Prevnar is further enhanced by its potential to deliver improved titers when co-administered with a flu vaccine.

On the other hand, on November 4, 2025, Vaxcyte, Inc. (NASDAQ:PCVX) released its Q3 2025 results. Closing the quarter with $2.7 billion in cash, the company noted consistent Phase II results for VAX-24 in infants. On that note, Vaxcyte reaffirmed its plans to initiate the VAX-31 critical adult trial in December.

Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company, develops high-fidelity conjugate vaccines. It helps prevent invasive pneumococcal disease, with its lead candidates, VAX-31 and VAX-24, aiming to provide broad-spectrum bacterial protection.

While we acknowledge the potential of PCVX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 7 Best Oil and Gas Penny Stocks to Buy According to Analysts and Billionaire Jacob Rothschild’s RIT Capital Partners: 9 Stocks with Huge Upside Potential.

Disclosure: None.